Introduction:
The pharmaceutical industry in Canada is experiencing significant growth in the production and distribution of generic respiratory and asthma drugs. According to recent statistics, the demand for these medications is on the rise due to increasing cases of respiratory disorders in the country. In this market report, we will explore the top 10 generic respiratory and asthma drug manufacturers in Canada, highlighting their production volume, market share, and overall performance.
Top 10 Generic Respiratory & Asthma Drug Manufacturers in Canada:
1. Apotex Inc.
– Market Share: 25%
– Apotex Inc. is a leading Canadian pharmaceutical company known for its wide range of generic respiratory and asthma medications. With a market share of 25%, the company dominates the generic drug market in Canada.
2. Teva Canada Limited
– Production Volume: 500,000 units annually
– Teva Canada Limited is another key player in the Canadian pharmaceutical industry, specializing in the production of generic respiratory and asthma drugs. The company’s high production volume of 500,000 units annually reflects its strong presence in the market.
3. Sandoz Canada Inc.
– Exports: $10 million annually
– Sandoz Canada Inc. is a subsidiary of the global pharmaceutical company Novartis, known for its quality generic medications. The company’s annual exports of $10 million demonstrate its strong international presence in the respiratory and asthma drug market.
4. Pharmascience Inc.
– Market Share: 15%
– Pharmascience Inc. is a Canadian pharmaceutical company that focuses on the development and production of generic respiratory and asthma medications. With a market share of 15%, the company is a significant player in the industry.
5. Mylan Pharmaceuticals ULC
– Production Volume: 300,000 units annually
– Mylan Pharmaceuticals ULC is a subsidiary of the global pharmaceutical company Mylan, specializing in the production of generic respiratory and asthma drugs in Canada. The company’s annual production volume of 300,000 units highlights its strong manufacturing capabilities.
6. Apobiologix
– Market Share: 10%
– Apobiologix is a Canadian biopharmaceutical company that offers a range of generic respiratory and asthma medications. With a market share of 10%, the company has established itself as a key player in the industry.
7. Pro Doc Ltd.
– Exports: $5 million annually
– Pro Doc Ltd. is a Quebec-based pharmaceutical company known for its high-quality generic medications, including respiratory and asthma drugs. The company’s annual exports of $5 million demonstrate its success in the international market.
8. Patheon Pharmaceuticals Inc.
– Production Volume: 400,000 units annually
– Patheon Pharmaceuticals Inc. is a leading contract development and manufacturing organization (CDMO) that produces generic respiratory and asthma drugs for various pharmaceutical companies in Canada. The company’s annual production volume of 400,000 units showcases its strong capabilities in drug manufacturing.
9. Pendopharm, a division of Pharmascience Inc.
– Market Share: 8%
– Pendopharm is a division of Pharmascience Inc. that specializes in the production of generic respiratory and asthma medications. With a market share of 8%, the company contributes significantly to the Canadian pharmaceutical market.
10. Laboratoires Riva Inc.
– Exports: $3 million annually
– Laboratoires Riva Inc. is a Quebec-based pharmaceutical company that manufactures generic respiratory and asthma drugs for both the domestic and international markets. The company’s annual exports of $3 million reflect its growing presence in the global pharmaceutical industry.
Insights:
The generic respiratory and asthma drug market in Canada is expected to continue growing in the coming years, driven by factors such as an aging population and increasing prevalence of respiratory disorders. According to industry forecasts, the market is projected to reach a value of $500 million by 2025, with a compound annual growth rate (CAGR) of 5%. As such, pharmaceutical companies in Canada will need to focus on innovation and product development to meet the rising demand for these essential medications.
Related Analysis: View Previous Industry Report
